Profile: Pacira Biosciences Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

1:30am IST
Change (% chg)

$-0.36 (-0.83%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc., incorporated on December 22, 2006, is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration (FDA)-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

EXPAREL provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL is designed to provide extended pain management using a single injection. It is advancing a Phase IV multicenter, randomized, double-blind, controlled trial of EXPAREL for postsurgical pain management in patients undergoing open lumbar spinal fusion surgery. It is also evaluating EXPAREL for nerve block. It has enrolled patients in both of its EXPAREL Phase III trials for upper and lower extremity nerve blocks, specifically a femoral nerve block for patients undergoing Total Knee Arthroplasty (TKA), and a brachial plexus nerve block for patients undergoing either total shoulder arthroplasty or rotator cuff repair procedures.

DepoCyt(e) is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine utilizing its DepoFoam technology. DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis. DepoTXA is used off-label as a systemic injection or as a topical application, and is used to treat or prevent excessive blood loss during surgery by preventing the breakdown of a clot. DepoTXA is in Phase II clinical development. DepoMLX is a long-acting non-steroidal anti-inflammatory drug (NSAID), which is designed to treat moderate to severe acute postsurgical pain as part of a non-opioid multimodal regimen.

The Company competes with Halyard Health, Inc.

Company Address

Pacira Biosciences Inc

5 Sylvan Way Ste 300
PARSIPPANY   NJ   07054-3813
P: +1973.2543560
F: +1302.6555049

Company Web Links